Triple negative breast cancer is one of the most difficult kinds of breast cancer to treat, it grows fast and historically ...
SurvivorNet on MSN
New data and FDA approval brings hope for metastatic triple-negative breast cancer
Two major studies are looking at moving sacituzumab govitecan earlier for metastatic triple-negative breast cancer.
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line ...
Sacituzumab govitecan is the first ADC approved for upfront metastatic triple-negative breast cancer regardless of PD-L1 ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...
Triple-negative breast cancer (TNBC) is aggressive and hard to treat. But the role of fat tissue in how the cancer spreads ...
MedPage Today on MSN
TROP2 drug wins two new indications in triple-negative breast cancer
Sacituzumab govitecan approved alone or in combination for first-line treatment ...
EMA committee recommends approval of AstraZeneca & Daiichi Sankyo’s Datroway for 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy: C ...
Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...
Adjuvant chemotherapy is associated with improved breast cancer-specific and overall survival in women aged 70 years or older with nonmetastatic triple-negative breast cancer, according to a US ...
June 2026Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Recommendation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results